Sysmex Europe

FIT performance and cut-off value selection in CRC screening

In Europe, colorectal cancer (CRC) is the most prevalent of all tumours, with 471,000 cases diagnosed per year and second only to lung cancer in terms of deaths. Yet studies show that it is possible to reduce mortality significantly by adopting population-based CRC screening programmes which allow the early detection of CRC. Due to its simplicity and proven superior performance, faecal immunochemical test (FIT) is currently considered the best non-invasive faecal occult blood (FOB) test for CRC screening. Moreover, considering both positivity rate and colonoscopy capacity, the FIT cut-off can be adjusted to meet screening goals.
File type:
File size:
394 KB



Copyright © Sysmex Europe SE. All rights reserved.